Phase II Study of S-877489 in Pediatric Patients with Attention-deficit/Hyperactivity Disorder -Long Term Extension Study-
Latest Information Update: 20 May 2022
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Shionogi
- 16 Jan 2017 Status changed from active, no longer recruiting to completed.
- 03 Jun 2016 New trial record